rather, it facilitates gradual, sustained weight management and reduction within a reasonable timeline
Semaglutide, a key component of both Ozempic and Wegovy, is a GLP-1 receptor agonist that plays a vital role in regulating insulin secretion and appetite, which are essential for managing type 2 diabetes and supporting weight loss efforts
A notable research effort, known as the STEP (Semaglutide GLP-1 Treatment Effect in People with Obesity) trial, revealed that participants taking Semaglutide GLP-1 achieved an average weight reduction of around 15% of their starting body weight within 68 weeks, unlike those taking a placebo
Semaglutide is also used as a prescription weight loss medication for adults who do not have diabetes
Absorption and Effectiveness : Caffeinated drinks might impact the absorption of Semaglutide, potentially reducing its effectiveness
Check the commitment and cancellation policy